Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell L Shiffman

Showing results (81-90 of 209) with videos related to

Pageof 21
Sort By:
The American Journal of Gastroenterology|April 6, 2016
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsMitchell L Shiffman, Vinod Rustgi, Michael Bennett, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 25, 2006
Chronic hepatitis C in patients with persistently normal alanine transaminase levelsMitchell L Shiffman, Moisés Diago, Albert Tran, et al.
The American Journal of Gastroenterology|June 3, 2005
Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis CR Todd Stravitz, Harold Chung, Richard K Sterling, et al.
Hepatology (Baltimore, Md.)|March 28, 2008
Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfectionRichard K Sterling, Melissa J Contos, Paula G Smith, et al.
Hepatology (Baltimore, Md.)|August 20, 2010
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis CFred Poordad, Eric Lawitz, Mitchell L Shiffman, et al.
Annals of Hepatology|June 14, 2014
Long term changes in liver histology following treatment of chronic hepatitis C virusMitchell L Shiffman, Richard K Sterling, Melissa Contos, et al.
Gastroenterology & Hepatology|June 23, 2010
Herpes simplex virus colitis in a patient with Crohn's disease and hepatitis B and d cirrhosisJenny O Smith, Richard K Sterling, A Scott Mills, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2003
The clinical spectrum of hepatitis C virus in HIV coinfectionRichard K Sterling, Melissa J Contos, Arun J Sanyal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 1, 2004
Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfectionRichard K Sterling, Mary S Wilson, Arun J Sanyal, et al.
The New England Journal of Medicine|July 13, 2007
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3Mitchell L Shiffman, Fredy Suter, Bruce R Bacon, et al.
Pageof 21

Showing results (81-90 of 209) with videos related to

Sort By:
Pageof 21
The American Journal of Gastroenterology|April 6, 2016
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsMitchell L Shiffman, Vinod Rustgi, Michael Bennett, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 25, 2006
Chronic hepatitis C in patients with persistently normal alanine transaminase levelsMitchell L Shiffman, Moisés Diago, Albert Tran, et al.
The American Journal of Gastroenterology|June 3, 2005
Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis CR Todd Stravitz, Harold Chung, Richard K Sterling, et al.
Hepatology (Baltimore, Md.)|March 28, 2008
Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfectionRichard K Sterling, Melissa J Contos, Paula G Smith, et al.
Hepatology (Baltimore, Md.)|August 20, 2010
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis CFred Poordad, Eric Lawitz, Mitchell L Shiffman, et al.
Annals of Hepatology|June 14, 2014
Long term changes in liver histology following treatment of chronic hepatitis C virusMitchell L Shiffman, Richard K Sterling, Melissa Contos, et al.
Gastroenterology & Hepatology|June 23, 2010
Herpes simplex virus colitis in a patient with Crohn's disease and hepatitis B and d cirrhosisJenny O Smith, Richard K Sterling, A Scott Mills, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2003
The clinical spectrum of hepatitis C virus in HIV coinfectionRichard K Sterling, Melissa J Contos, Arun J Sanyal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 1, 2004
Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfectionRichard K Sterling, Mary S Wilson, Arun J Sanyal, et al.
The New England Journal of Medicine|July 13, 2007
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3Mitchell L Shiffman, Fredy Suter, Bruce R Bacon, et al.
Pageof 21